Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER-2/neu Overexpressing Breast Tumor Xenografts

PURPOSE: We have shown that incomplete blockade of the Human Epidermal Growth Factor (HER) pathway is a mechanism of resistance to treatment with trastuzumab (T) in HER2-overexpressing tumor xenografts. We now investigate whether the addition of lapatinib (L), a dual HER1/2 kinase inhibitor, to T re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rimawi, Mothaffar F., Wiechmann, Lisa S., Wang, Yen-Chao, Huang, Catherine, Migliaccio, Ilenia, Wu, Meng-Fen, Gutierrez, Carolina, Hilsenbeck, Susan G., Arpino, Grazia, Massarweh, Suleiman, Ward, Robin, Soliz, Robert, Osborne, C. Kent, Schiff, Rachel
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3060302/
https://ncbi.nlm.nih.gov/pubmed/21138857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1905
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares